Rubius Therapeutics (RUBY) Issues Strategic Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/28/2026
- Wall Street ends mixed as investors focus on tech earnings
- NVIDIA’s rising CDS the talk of Wall Street amid circular financing fears
- U.S. chip stocks extend losses on AI financing, China competition fears
- Tesla to buy power from Arizona solar project
- Why BofA says July Fed rate hike would be "unprecedented"
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- Applied Digital (APLD) Tops Q4 EPS by 23c, Revenue Beats
- BuzzFeed cuts 35% of workforce in restructuring move
Morgan Stanley on Rubius (RUBY) New Strategy and Restructuring: 'removes potential for near-term clinical catalyst'
September 13, 2022 9:48 AM EDTMorgan Stanley analyst Jeffrey Hung reiterated an Equalweight rating and $1.50 price target on Rubius (NASDAQ: RUBY).
The analyst comments "Our Take: Update removes potential for near-term clinical catalysts. We acknowledge the potential advantages of the next-gen platform and understand streamlining the... More
